APLM
Apollomics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-3.51
P/S
2.23
EV/EBITDA
-0.50
DCF Value
$6.98
FCF Yield
-82.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-22.7%
Operating Margin
-395.9%
Net Margin
-450.0%
ROE
-13385.4%
ROA
-280.5%
ROIC
-3227.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $8.5M | $-12.5M | $-11.37 |
| Q4 2024 | $-1.6M | $-18.7M | $-16.92 |
| FY 2024 | $198.0K | $-53.9M | $-52.80 |
| Q2 2024 | $1.8M | $-35.2M | $-38.00 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.83
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.